ELVN (Enliven Therapeutics) Marketable Securities : $189.32 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Enliven Therapeutics's Marketable Securities for the quarter that ended in Dec. 2024 was $189.32 Mil.

Enliven Therapeutics's annual Marketable Securities increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($153.01 Mil) and increased from Dec. 2023 ($153.01 Mil) to Dec. 2024 ($189.32 Mil).

Enliven Therapeutics Marketable Securities Historical Data

The historical data trend for Enliven Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics Marketable Securities Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

153.01

189.32

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial										153.01	171.34	215.52	191.21	189.32

Enliven Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Enliven Therapeutics (NAS:ELVN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Enliven Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Executives

Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Rahul D. Ballal	director, officer: President & CEO	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Mika K Derynck	director	C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107